Physician profile
William H Nesbit
NPI 1083887798
$3,020.37
in general payments reported to CMS, 2019-2025
34 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $270 · 2021: $25.97 · 2022: $367 · 2023: $654 · 2024: $422 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.03 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $515.53 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $328.35 | 2019-2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $317.20 | 2020-2024 | |
| Axsome Therapeutics, INC. | $216.64 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $163.64 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.49 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $114.24 | 2019 | |
| Harmony Biosciences LLC | $110.75 | 2023-2025 | Wakix |
| Novartis Pharmaceuticals Corporation | $107.69 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $106.53 | 2023-2024 | Inpefa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.32 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $95.89 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $86.05 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Paratek Pharmaceuticals, INC. | $70.31 | 2023-2024 | Nuzyra |
| Abbott Laboratories | $60.93 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $57.20 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.21 | 2022 | |
| Pfizer INC. | $44.94 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $37.46 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.64 | 2024 | |
| Astellas Pharma US INC | $34.28 | 2023 | Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $24.94 | 2023 | Ajovy |
| Averitas Pharma INC. | $22.39 | 2025 | Qutenza |
| Sumitomo Pharma America, INC. | $20.70 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $20.13 | 2023 | Spravato |
| Allergan, INC. | $19.94 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.90 | 2019 | |
| Gilead Sciences, INC. | $17.22 | 2025 | |
| Radius Health, INC. | $16.07 | 2019 | |
| Sage Therapeutics, LLC | $15.29 | 2024 | |
| Viiv Healthcare Company | $14.79 | 2025 | Apretude |
| Collegium Pharmaceutical, INC. | $14.41 | 2025 | Belbuca |
| Supernus Pharmaceuticals, INC. | $14.16 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $14.14 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Nesbit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.